Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Can J Cardiol. 2022 Nov;38(11):1742-1750. doi: 10.1016/j.cjca.2022.07.018. Epub 2022 Aug 4.
There are limited data on the prognostic role of hepatorenal function indices in ambulatory patients with congenital heart disease (CHD). The purpose of this study was to determine the prevalence, risk factors, and prognostic implications of hepatorenal dysfunction, as measured by Model for End-Stage Liver Disease Excluding International Normalised Ratio (MELD-XI) score, in adults with CHD.
In this retrospective study of CHD patients with comprehensive metabolic panels (2003-2019), mild/moderate and severe hepatorenal dysfunction was defined as MELD-XI 11-15 and > 15, respectively.
Of 4977 patients, 1376 (28%) had hepatorenal dysfunction (mild/moderate: n = 935 [19%]; severe: n = 441 [9%]). Hepatorenal dysfunction was most common in Fontan/unrepaired single ventricle (46%) and right heart disease (31%). Baseline MELD-XI was associated with all-cause mortality (HR 1.27, CI 1.21-1.33; P < 0.001) after adjustment for age, sex, and congenital heart lesion. In 3864 patients with serial MELD-XI data, there was a temporal increase in MELD-XI, and this was associated with an increased risk of mortality (HR 1.24, CI 1.15-1.36, per unit increase in MELD-XI; P = 0.004), independently from the baseline MELD-XI score. In the subset of 1856 patients that underwent surgical/transcatheter interventions, there was a postoperative reduction in MELD-XI, and this was associated with a lower risk of mortality (HR 0.94, CI 0.90-0.98, per unit decrease in MELD-XI; P = 0.008), independently from the baseline MELD-XI score.
Hepatorenal dysfunction was common in adults with CHD. Both baseline MELD-XI score and temporal changes in MELD-XI were associated with clinical outcomes, and therefore could be used to monitor therapeutic response to interventions and for deterioration in clinical status.
目前关于肝功能和肾功能指标在门诊先天性心脏病(CHD)患者中的预后作用的数据有限。本研究旨在通过终末期肝病模型排除国际标准化比值(MELD-XI)评分来确定 CHD 成人肝肾功能障碍的患病率、危险因素和预后意义。
在这项 2003 年至 2019 年期间对 CHD 患者进行的综合代谢组学研究中,将轻度/中度和重度肝肾功能障碍定义为 MELD-XI 为 11-15 和> 15。
4977 例患者中,1376 例(28%)存在肝肾功能障碍(轻度/中度:935 例[19%];重度:441 例[9%])。肝肾功能障碍最常见于法洛四联症/未修复的单心室(46%)和右心疾病(31%)。校正年龄、性别和先天性心脏病变后,基线 MELD-XI 与全因死亡率相关(HR 1.27,95%CI 1.21-1.33;P<0.001)。在 3864 例有连续 MELD-XI 数据的患者中,MELD-XI 呈时间性增加,这与死亡率增加相关(HR 1.24,95%CI 1.15-1.36,MELD-XI 每增加一个单位;P=0.004),与基线 MELD-XI 评分无关。在 1856 例接受手术/经导管干预的患者亚组中,MELD-XI 术后降低,与死亡率降低相关(HR 0.94,95%CI 0.90-0.98,MELD-XI 每降低一个单位;P=0.008),与基线 MELD-XI 评分无关。
肝肾功能障碍在 CHD 成人中很常见。基线 MELD-XI 评分和 MELD-XI 的时间变化与临床结局相关,因此可用于监测干预治疗的反应和临床状态的恶化。